Navigation Links
Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
Date:4/27/2009

COPENHAGEN, April 27 /PRNewswire/ -- As a testimony to the strength of Santaris Pharma's efficient Drug Discovery Engine, the Company announced today the completion of the delivery of six cancer target drug candidates to their collaboration partner Enzon Pharmaceuticals. All six drug candidates have been designed, synthesized and selected in collaboration with Enzon, within 24 months of commencing the collaboration.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Our collaboration with Enzon Pharmaceuticals has been very productive and goal oriented enabling both companies to benefit optimally from our ability to rationally design, discover and select potent and safe RNA targeted drugs within a short time span," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer.

Santaris Pharma and Enzon Pharmaceuticals signed their agreement in 2006. As part of the agreement Santaris Pharma retains the lucrative commercial rights to the drugs within Europe. The agreement included two LNA based RNA inhibitors at the pre-clinical stage, EZN2968 against HIF-1ÿ±, and EZN3042 against Survivin, both of which are currently in Phase I studies conducted by Enzon, and the development of six additional cancer target drugs selected by Enzon which are in various stages of preclinical development.

"We are encouraged by the data generated by the first two lead candidates," said Dr. Ivan Horak, Executive Vice President of Research, Development and Chief Scientific Officer, Enzon Pharmaceuticals. "In addition, I'm pleased to see the continued validation of the Locked Nucleic Acid (LNA) technology as we continue to evaluate the additional targets in preclinical programs."

http://www.santaris.com

Santaris Pharma (founded in 2003)
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
5. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
6. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
7. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
8. Helix BioPharma to Present at the BioFinance 2009 Conference
9. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... According to new market research report "Data Center ... Telecom), by Design Types (Electrical, Mechanical), and by ... Tier 4) - Global Forecast to 2019", published ... Construction Market into various segments with an in-depth ... also identifies the factors driving this market, various ...
(Date:10/25/2014)... TX (PRWEB) October 24, 2014 Today, ... products, announced the winners of its “Reflect Your Youth” ... have not only seen a difference in their skin ... experienced a new outlook on life as a result ... contest originated as an effort by Nerium International to ...
(Date:10/25/2014)... 2014 Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, announced ... will present at FireRock Capital,s Micro-Cap Conference. ... ,Date: Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: ... City , About The FireRock ...
(Date:10/25/2014)... , Oct 24, 2014 Research and ... "Epigenetics Market by Product , Research Area & by ... to their offering. In this report, ... of products, research areas, and end users. The product ... are enzymes, instruments & consumables, kits, and reagents. The ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3
... 10, 2011 Boston Scientific Corporation (NYSE: ... a clinical education program and online resource center for ... spinal cord stimulation (SCS) technology, procedures and techniques.  The ... the International Spine Intervention Society (ISIS) occurring this week ...
... Verenium Corporation (Nasdaq: VRNM ), a leading industrial ... enzymes, today reported a summary of recent Company highlights and ... June 30, 2011. "I am very pleased with ... partnership negotiations in the first half of the year," said ...
... NEW YORK, Aug. 9, 2011 Reportlinker.com ... is available in its catalogue: ...     http://www.reportlinker.com/p0591346/ ... Biochips, DNA Chips, Genosensors, Microarrays and Labs-on-the-Chip ...
Cached Biology Technology:Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 2Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 3Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9Biochips: Genosensors, Microarrays, Labs-On-The-Chip 2
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... when a mouse repeatedly experiences defeat by a dominant ... memory molecule in a brain circuit for social learning, ... National Institute of Mental Health (NIMH) have discovered. ... welcome strangers in spite of repeated social defeat. Their ...
... cure rate for the once almost universally fatal childhood ... in the near future, thanks to improvements in diagnosis ... investigators at St. Jude Children's Research Hospital. Almost 4,000 ... each year, about two-thirds of which are in children ...
... in repairing damaged DNA causes mice to develop the ... have discovered. , Scientists at OHSU, the University of ... that generating mice that lack the gene encoding the ... obesity and reach nearly twice the weight of their ...
Cached Biology News:Mice lacking social memory molecule take bullying in stride 2Mice lacking social memory molecule take bullying in stride 3St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Removing DNA repair gene causes metabolic syndrome 2Removing DNA repair gene causes metabolic syndrome 3
... service involves the optimization of ... titration of the primary antibody, ... reagents (e.g. Alk. Phos., HRP, ... of detection, evaluation by light ...
Request Info...
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Biology Products: